WilliamYKimMD
Oncology • Chapel Hill, NCGenitourinary Oncology, Hematologic Oncology
Professor, Medicine and Genetics, University of North Carolina at Chapel Hill School of Medicine
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-4996Fax+1 919-843-5515- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1996 - 1999
The Warren Alpert Medical School of Brown UniversityClass of 1996
Certifications & Licensure
NC State Medical License 2006 - 2024
MA State Medical License 1999 - 2006
Clinical Trials
- Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer Start of enrollment: 2009 May 01
- Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy Start of enrollment: 2012 Jun 01
- Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.Okato, A., Utsumi, T., Ranieri, M., Zheng, X., Zhou, M., Pereira, L., Chen, T., Kita, Y., Wu, D., Hyun, H., Lee, H., Gdowski, A., Raupp, J., Clark-Garvey, S., Manocha,...> ;The Journal of Clinical Investigation. 2024 Jan 16
- 1 citationsSpatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.Wolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, Bentley Midkiff, Gabriela De la Cruz, Vladmir Makarov, Leah Flick, Mark G Woodcock, Petros Grivas, Marc A Bjurlin...> ;European Urology. 2024 Mar 1
- Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.Weiss, K., Miller, K., Abimbola, O., Kim, W., Rose, T., Bjurlin, M., Gessner, K.> ;Urology. 2024 Feb 1
- Join now to see all
Journal Articles
- VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell CarcinomaEric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
Press Mentions
Newsworthy from the School of Medicine, Week of August 12 – 19August 18th, 2021
GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)February 13th, 2020- GeneCentric Therapeutics Enters Bladder Cancer Research Collaboration with University of North CarolinaDecember 10th, 2018
- Join now to see all
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
